VivoSeq
Gastroenterology

Inguinal Hernia

51

Pipeline Programs

12

Active Trials

21

Companies Involved

Inguinal hernia is a moderately active landscape with 51 programs across 21 companies. The most active players are Shanghai Hengrui Pharmaceutical Co., Ltd., AstraZeneca, Pacira Pharmaceuticals, Inc. 15 therapies are approved with 9 more in late-stage development.

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

27/100

Mech. Concentration

12/100

Completion Rate

94/100

Attrition Rate

3/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

99%

Small molecule

66 of 67 classified programs — the dominant modality here.

1%ALL OTHERSProtein / enzyme11%

Small molecule leads; the ring shows all 67 classified programs, each share of the total. Modality classified for 100% of 67 pipeline programs.

Trial Status

62

clinical trials

Completed34 · 55%
Unknown status14 · 23%
Recruiting6 · 10%
Not yet recruiting3 · 5%
Active, not recruiting3 · 5%
Withdrawn2 · 3%

Trial Activity

62 trials

No Opioids vs. Minimal Opioids Following Inguinal Hernia Repair
Active, not recruiting··Phase 4·NCT05929937·904 enrolled
Intrathecal Morphine for Inguinal Hernia Repair.
Completed··Phase 4·NCT02001948·46 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)